Deferred combined androgen blockade therapy using antiandrogen in hormone-refractory metastatic prostate cancer patients treated with Degarelix, GnRH antagonist
Not Applicable
Recruiting
- Conditions
- Bone metastatic prostate cancer
- Registration Number
- JPRN-UMIN000011437
- Lead Sponsor
- Osaka University Graduate School of Medicine, Department of Organ Specific Regulation (Urology)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Previous or present endocrine treatment for prostate cancer.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method